BioSpace News Archive

Feb. 10, 2020 12:45 UTC “Take on Acne” ad campaign emphasizes the discomfort and disruption caused by acne, especially among teens and young adults PRINCETON, N.J.--( BUSINESS WIRE )-- Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (together “Sun Pharma”), today announced the launch of Take on Acne – a new advertising campaign designed to raise awareness of the profound imp

McKesson Corporation (NYSE:MCK) today announced the commencement of an exchange offer for the split-off of its wholly-owned subsidiary, PF2 SpinCo, Inc. (“SpinCo”), which will hold all of McKesson’s interest in Change Healthcare LLC (“Change Healthcare”), as part of McKesson’s previously announced agreement with Change Healthcare Inc. (Nasdaq:CHNG) (“Change”) to merge SpinCo with and into Change.

HOUSTON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the Noble Capital Markets’ 16 th Annual Small & Microcap Investor Conference (NobleCon 16) being held February 16-18, 2020 in Hollywood, FL. Details of Salarius’ presentations are as follows: Event: Noble Capital

Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B (HBV) specific RNA-destabilizer, and to continue research and development of a next generation oral HBV RNA-destabilizer.

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that new clinical data on the Company’s first-in-class, late-stage asset, Plinabulin, shows its ability to potently stimulate the innate immune system.

Nanoform, an innovative nanoparticle medicine enabling company, has established Nanoform USA Inc., a wholly owned subsidiary in the US.

Clover Biopharmaceuticals announced that it has successfully produced its trimeric Spike-protein subunit vaccine candidate for 2019-nCoV via a mammalian cell expression system.

Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic

Freudenberg Medical, a global developer and manufacturer of medical devices, components, and minimally invasive solutions, will be exhibiting at MD&M West alongside Freudenberg Medical companies VistaMed, Cambus Medical, Hemoteq, and Freudenberg Performance Materials.

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, February 27, 2020 at 8:00 a.m. EST to report its fourth quarter and full year 2019 financial results and discuss recent business updates.